<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970213</url>
  </required_header>
  <id_info>
    <org_study_id>GGPS19-01</org_study_id>
    <nct_id>NCT03970213</nct_id>
  </id_info>
  <brief_title>Intravenous Tranexamic Acid During Rhytidectomy</brief_title>
  <official_title>Effects of Intravenous Tranexamic Acid During Rhytidectomy - a Randomized, Controlled, Double-blind Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glasgold Group Plastic Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glasgold Group Plastic Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind study investigating whether intravenous
      tranexamic acid has any effect on rhytidectomy surgery, or the subsequent postoperative
      sequelae. Intraoperative bleeding and postoperative ecchymosis and edema are subjectively
      rated and complications are noted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind pilot study investigating whether intravenous
      tranexamic acid has any effect on rhytidectomy surgery, or the subsequent postoperative
      sequelae. Intraoperative bleeding is rated on a scale of mild, moderate, or severe and given
      a score of 1-3. Postoperative ecchymosis and edema are subjectively rated by both patient and
      surgeon on postoperative days 1, 6, and 9 using a similar mild/moderate/severe scale and
      scored 1-3, respectively. Any surgical or postoperative complications are noted. Scores are
      aggregated for statistical analysis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only the CRNA who is administering the medications is unmasked until completion of the data collection period.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative bleeding</measure>
    <time_frame>Surgical time</time_frame>
    <description>Subjective measure of intraoperative blood loss (mild, moderate, or severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative ecchymosis</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Subjective measure of bruising rated as mild, moderate, or severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative ecchymosis</measure>
    <time_frame>Postoperative day 6</time_frame>
    <description>Subjective measure of bruising rated as mild, moderate, or severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative ecchymosis</measure>
    <time_frame>Postoperative day 9</time_frame>
    <description>Subjective measure of bruising rated as mild, moderate, or severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative edema</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Subjective measure of swelling rated as mild, moderate, or severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative edema</measure>
    <time_frame>Postoperative day 6</time_frame>
    <description>Subjective measure of swelling rated as mild, moderate, or severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative edema</measure>
    <time_frame>Postoperative day 9</time_frame>
    <description>Subjective measure of swelling rated as mild, moderate, or severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative hematoma/seroma</measure>
    <time_frame>10 days postoperative</time_frame>
    <description>Documentation of any postoperative collections seen during the first 10 days following surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>10 days postoperative</time_frame>
    <description>Documentation of any surgical or postoperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bleeding</condition>
  <condition>Bruising Face</condition>
  <condition>Swelling Lips &amp; Face</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TXA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid 100Mg/Ml Inj Vil 10Ml</intervention_name>
    <description>IV TXA given during surgery</description>
    <arm_group_label>TXA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 0.9% Infusion Solution Bag</intervention_name>
    <description>IV saline given during surgery</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing rhytidectomy surgery at Glasgold Group Plastic Surgery

        Exclusion Criteria:

          -  History of bleeding disorder, history of thromboembolic events, history of seizure,
             active use of oral contraceptive pills or hormone replacement therapy, participant
             preference
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Glasgold, MD</last_name>
    <role>Study Director</role>
    <affiliation>Glasgold Group Plastic Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark J Glasgold, MD</last_name>
    <phone>732-846-6540</phone>
    <email>mglasgold@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justin C Cohen, MD</last_name>
    <phone>732-846-6540</phone>
    <email>justinccohen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Glasgold Group Plastic Surgery</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark J Glasgold, MD</last_name>
      <phone>732-846-6540</phone>
      <email>mglasgold@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert A Glasgold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>Rhytidectomy</keyword>
  <keyword>Facelift</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Contusions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient demographics, surgical procedure performed, primary and secondary outcomes</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Will be made available via publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

